Having trouble accessing articles? Reset your cache.

Testing the tech transfer model

TaiGen Biotechnology Co. Ltd.'s financing and technology deal with Arena Pharmaceuticals Inc. demonstrates the power of personal relationships as well as providing the most high-profile milestone in the effort to build a fledgling biotechnology sector in Taiwan. Now what remains to be seen is whether the $37 million start-up deal will provide a successful proof of principle for the technology transfer model for industrial development.

TaiGen is launching operations with the series A financing also announced last week, with the investors including MPM Capital; Development Fund; Yuen Foo

Read the full 877 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers